Overview

Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients

Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
0
Participant gender:
All
Summary
This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Desvenlafaxine Succinate
Criteria
Inclusion Criteria:

Patients diagnosed with major depressive disorder and vasomotor symptoms secondary to
menopause prescribed with desvenlafaxine succinate

Exclusion Criteria:

Hypersensitivity to desvenlafaxine succinate